Interim report January–September 2025: Progress in the right direction
Summary by AI BETAClose X
Surgical Science Sweden AB reported a third-quarter net sales increase of 14 percent to SEK 263.6 million, with local currency sales up 19 percent, though operating profit decreased to SEK 27.2 million from SEK 45.8 million due to SEK 1.5 million in restructuring costs related to the Intelligent Ultrasound acquisition. Net profit fell to SEK 20.4 million, or SEK 0.40 per share, compared to SEK 43.0 million, or SEK 0.84 per share, in the prior year, and cash flow from operating activities was negative SEK 4.4 million. For the first nine months, net sales rose 14 percent to SEK 723.5 million, but operating profit significantly declined to SEK 28.7 million from SEK 105.2 million, impacted by SEK 22.6 million in acquisition costs and SEK 5.3 million in restructuring costs.
Third quarter 2025 (July – September)
- Net sales amounted to SEK 263.6 (231.8) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 19 percent.
- Sales of SEK 18.8 million from Intelligent Ultrasound are included in the figures. For comparable units, sales increased by 6 percent.
- License revenue amounted to SEK 65.5 (65.0) million and accounted for 25 (28) percent of net sales.
- The gross margin was 65 (69) percent.
- Operating profit amounted to SEK 27.2 (45.8) million. The profit includes SEK 1.5 million in restructuring costs attributable to the acquisition of Intelligent Ultrasound. Currency effects of SEK -7.2 million (-2.1) are recognized on the line Other operating income and costs.
- Net profit amounted to SEK 20.4 (43.0) million, corresponding to earnings per share of SEK 0.40 (0.84).
- Cash flow from operating activities amounted to SEK -4.4 (22.1) million. As at September 30, 2025, cash and cash equivalents amounted to SEK 597.4 (666.3) million.
First nine months of 2025 (January – September)
- Net sales amounted to SEK 723.5 (632.5) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 20 percent.
- For comparable units, sales increased by 5 percent.
- License revenue amounted to SEK 208.3 (195.3) million and accounted for 29 (31) percent of net sales.
- The gross margin was 66 (68) percent.
- Operating profit amounted to SEK 28.7 (105.2) million. Profit includes SEK 22.6 million in acquisition costs and SEK 5.3 million in restructuring costs, both of which are attributable to the acquisition of Intelligent Ultrasound. Currency effects of SEK -30.2 million (5.5) are recognized on the line Other operating income and costs.
- Net profit amounted to SEK 33.6 (95.4) million, corresponding to earnings per share of SEK 0.66 (1.87).
- Cash flow from operating activities amounted to SEK 6.9 (80.6) million.
- Intelligent Ultrasound, which operates in the field of ultrasound simulation, was acquired in February. The acquisition date was February 18.
Gothenburg, Sweden, November 13, 2025
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund